Back to results

TerminatedPhase 3

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

NCT03909295

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Seto, Aichi-ken, Japan

+16 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2019-05-07
Enrollment: 52 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (17)

Novartis Investigative SiteSeto, Aichi-ken, Japan
Novartis Investigative SiteChikushino-shi, Fukuoka, Japan
Novartis Investigative SiteŌgaki, Gifu, Japan
Novartis Investigative SiteMaebashi, Gunma, Japan
Novartis Investigative SiteKanazawa, Ishikawa-ken, Japan
Novartis Investigative SiteMorioka, Iwate, Japan
Novartis Investigative SiteKan’onjichō, Kagawa-ken, Japan
Novartis Investigative SiteTakamatsu, Kagawa-ken, Japan
Novartis Investigative SiteYokohama, Kanagawa, Japan
Novartis Investigative SiteYokohama, Kanagawa, Japan
Novartis Investigative SiteSendai, Miyagi, Japan
Novartis Investigative SiteKashihara, Nara, Japan
Novartis Investigative SiteSayama, Saitama, Japan
Novartis Investigative SiteKusatsu, Shiga, Japan
Novartis Investigative SiteHachiōji, Tokyo, Japan
Novartis Investigative SiteItabashi-ku, Tokyo, Japan
Novartis Investigative SiteShinagawa-ku, Tokyo, Japan

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. — TrialFind